PNS Pharma is a leading provider of pharmaceutical reports that comprise extensive data, latest technologies, company and product profiles and many more.
Every research activity supposes holistic analysis and promotion of the drugs available at the market along with introduction of ongoing products with the detailed description of a manufacturing process chain. Thus, the clients obtain the following data and characteristics of the drug investigated:
- an original inventor;
- chemical formula;
- patent information;
- licensing;
- owner;
- stage of development according related to the sales territory.
PNS Pharma’s research activity covers the most diverse treatment medications including diabetes and endocrinology, respiratory and immunology, ophthalmology, oncology, infectious diseases, etc.
PNS Pharma has gained a big recognition due to its syndicated reports that together with a complex drug expertize perform company pipeline analysis. This enables to trace all the pharmaceuticals produced, monitor various therapeutic aspects and geographical areas where this product is used or developed.
Publications found:
61
Sort by:
Global Peptide Therapeutics Market & Clinical Pipeline Insight 2026
US$ 3,000.00
... Peptide Therapeutics, Peptide Vaccine & Peptide Hormone Global Peptide Therapeutics Market Dynamics Global Peptide Clinical Pipeline by Company, Indication & Phase Global Peptide Pipeline: 722 Peptides Majority Peptides in Preclinical Phase: 308 Peptides Commercially Available Peptides: 136 Peptides ...
January 2020
1500 pages
Global Cancer Monoclonal Antibodies Market &Clinical Trial Insight 2024
US$ 3,000.00
... for Monoclonal Antibodies for Cancer Treatment Global Cancer Monoclonal Antibodies Market Overview Global Cancer Monoclonal Antibodies Pipeline by Phase & Indication Global Cancer Monoclonal Antibodies Pipeline: 697 mAb Marketed Cancer Monoclonal Antibodies: 60 Global Cancer Monoclonal Antibodies Market ...
November 2018
1100 pages
Global Cancer Vaccine Market & Clinical Trial Insight 2025
US$ 3,000.00
... for cervical cancer and provenge for prostate cancer have already entered the market. Both the vaccines are therapeutic vaccines which have shown excellent outcome in the clinical trials. The ...
September 2018
700 pages
Enbrel Biosimilars Clinical Trial & Opportunity Insight
US$ 1,500.00
... Enbrel Biosimilars Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 36 biosimilar version of Enbrel drug in clinical pipeline. More than 5 of these biosimilars are in Phase-III trials ...
October 2016
70 pages
Humira Biosimilars Clinical Trial Insight
US$ 1,500.00
... Humira Biosimilars Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 33 biosimilars version of Humira drug in clinical pipeline. More than 10 of these biosimilars are in Phase-III trials ...
October 2016
80 pages
Herceptin (Trastuzumab) Biosimilar Clinical Trial Insight
US$ 1,500.00
... Herceptin (Trastuzumab) Biosimilar Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 37 biosimilar version of Herceptin drug in clinical pipeline. Currently there are 4 biosimilars in Phase-III trials ...
October 2016
85 pages
Lantus (Insulin Glargine) Biosimilar Clinical Trial & Opportunity Insight
US$ 1,000.00
... on the location. “Lantus (Insulin Glargine) Biosimilar Clinical Trial & Opportunity Insight” report by PNS Pharma gives comprehensive clinical insight on 37 biosimilar version of Lantus drug in clinical pipeline. Currently 5 biosimilar version of Lantus are commercially ...
October 2016
35 pages
Remicade (Infliximab) Biosimilar Clinical Trial Insight
US$ 1,200.00
... location. “Remicade (Infliximab) Biosimilar Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 17 biosimilar version of Remicade drug in clinical pipeline. Currently there are 2 biosimilars in Phase-III trials and are ...
October 2016
50 pages
Global Monoclonal Antibodies Pipeline Insight 2015
US$ 2,400.00
... Antibodies Global Monoclonal Antibodies Market Overview Global Monoclonal Antibodies Clinical Pipeline by Company, Indication & Phase Global Monoclonal Antibodies Clinical Pipeline: 1096 mAb Marketed Monoclonal Antibodies: 66 mAb Global Cancer Monoclonal Antibodies Clinical Pipeline: 602 mAb Marketed Cancer ...
March 2015
1600 pages
Global Peptide Therapeutics Pipeline Insight 2015
US$ 2,400.00
... size ... Peptide & Insulin “Global Peptide Therapeutics Pipeline Insight 2015” Report Highlights: Global Peptide Therapeutics Market Overview Global Peptide Therapeutics Pipeline By Peptide Type Global Peptide Therapeutics Pipeline By Company, Indication & Phase Peptide Therapeutics Clinical Pipeline: 743 Peptides ...
February 2015
1200 pages
Europe Orphan Drug Market & Clinical Trial Insight 2015
US$ 3,000.00
... most likely that the EU Regulation for Orphan medicinal products would have a significant impact in the coming years. “Europe Orphan Drug Market & Clinical ... Orphan Drug Status Comprehensive Insight on Orphan Drug Clinical Pipeline Europe Orphan Drug Clinical Pipeline: 326 Drugs Majority Orphan Designated ...
January 2015
1100 pages
Global Prostate Cancer Vaccine Clinical Pipeline Insight 2015
US$ 1,500.00
... body to activate the immune cells. They identify these antigens as non-self and begin to search and eliminate cancerous cells from body ... ” Report Highlights: Introduction to Prostate Cancer Vaccine Mechanism of Prostate Cancer Vaccine Global Prostate Cancer Vaccine Clinical Trial Insight by Company, Country ...
January 2015
155 pages
Small Molecule Cancer Drug Clinical Pipeline Insight
US$ 2,400.00
... the treatment of Non-Small Cell Lung Cancer (NSCLC), Colon cancer, Breast and other cancers. Development of small molecule cancer drug generally ... Insight” Report Findings: Role of Small Molecule Drug in Cancer Treatment Mechanism of Small Molecule Cancer Drug Small Molecule Cancer Drugs Market Dynamics ...
January 2015
1650 pages
Intramuscular Drug Delivery Market & Pipeline Insight
US$ 2,400.00
... The higher sales will depend upon efficacy of newly developed intramuscular drug and marketing strategy to drive its sales. They are used ... supposed to be cost effective along with pharmacologically efficient and minimized side effects. “Intramuscular Drug Delivery Market & Pipeline Insight” Report Findings: ...
January 2015
900 pages
Subcutaneous Drug Delivery Market & Pipeline Insight
US$ 2,400.00
... life threatening effects. Also, every year large number of protein based drugs are introduced in market for the treatment of various ailments. ... innovative products with higher therapeutic capabilities will enter in market in coming years. “Subcutaneous Drug Delivery Market & Pipeline Insight” Report Findings ...
January 2015
1800 pages
US Orphan Drug Clinical Pipeline Insight 2014
US$ 2,000.00
... disorders, which are extremely life-threatening. As per the official definition, rare diseases are classified as those that affect fewer than 200, ... & FDA Regulatory Framework US Orphan Drug Pipeline by Phase, Indication & Company Marketed Orphan Drug Clinical Insight US Orphan Drug Clinical Pipeline: 570 ...
August 2014
2000 pages
US CNS Disorders Drug Pipeline Insight 2014
US$ 2,400.00
... purchasing Hard Copy License depending on the location. The Central Nervous System (CNS) disorders market in US is one of the largest segments of pharmaceuticals industry ... with launch of novel drugs will drive the growth of CNS disease market in future. “US CNS Disorders Drug Pipeline Insight 2014” Report ...
August 2014
1700 pages
Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014
US$ 2,000.00
... trials studies have demonstrated the fact that the potential of peptide based drugs to prevent and eradicate cancer is far effective than conventional ... therapy, both conventional and peptide based cancer therapeutics are used for the treatment. “Global Peptide Cancer Therapeutics Market & Pipeline Insight ...
August 2014
556 pages
Cancer Cytokines Therapy Pipeline Analysis
US$ 1,800.00
... are related to almost all the therapeutic protein drug development processes. The cytokine and growth factor related products include antibodies ... improve quality of life. “Cancer Cytokines Therapy Pipeline Analysis” Report Highlights: Cancer Cytokines Therapy Market Overview Marketed Drug Profiles & Patent ...
June 2014
231 pages
Human Papillomavirus Infections Vaccine Pipeline Analysis
US$ 1,800.00
... could thus be used as a basis of the vaccine. There are only 2 HPV vaccines which are currently marketed across the globe. Both ... to treat it, either through drugs or through vaccines. “Human Papillomavirus Infections Vaccine Pipeline Analysis” Report Highlights: Human Papillomavirus Vaccine Market Overview ...
June 2014
197 pages
Cervical Cancer Drug Market & Pipeline Insight
US$ 1,800.00
... are also being analyzed. A majority of these studies were previously focusing on cervical cells in women. But in recent years, the realm of research has ... lead to the growth of abnormal cells, thus controlling the incidence of cervical cancer. “Cervical Cancer Drug Market & Pipeline Insight” Report Highlights ...
June 2014
165 pages
Schizophrenia Drug Market & Pipeline Insight
US$ 1,200.00
... offers much potential for future prevention and cure over the next two decades. “Schizophrenia Drug Market & Pipeline Insight” Report Highlights: Schizophrenia Drug Market Overview Marketed Drug Profiles & Patent Analysis Clinical Trial Insight by Phase & Country Drug in Clinical Development Phase: ...
June 2014
386 pages
Crohn’s Disease Drug Market and Pipeline Analysis
US$ 1,800.00
... the diagnostic techniques as the researchers would get a deeper understanding of the disease. Thus, overall, there is significant amount of research currently underway for ... , it is most likely that this market would offer better solutions for the patients. “Crohn’s Disease Drug Market and Pipeline Analysis” ...
May 2014
297 pages
Global Peptide Therapeutics Market & Pipeline Insight
US$ 2,400.00
... in the pre-clinical studies. There are many applications of the peptide drugs. The most popular and dominant segments include cancer ... demand for peptide drugs, this market is expected to grow at a CAGR of 9-10% to reach approximately USD 27.3 billion by 2018. “Global Peptide Therapeutics Market & Pipeline ...
February 2014
1350 pages
Europe Alzheimer's Disease Drug Pipeline Analysis
US$ 1,500.00
... / Originator/ Licensee/Collaborator Administrative Route Drug Class ATC Codes Europe Alzheimer’s Disease Drug Pipeline by Clinical Phase: Research: 19 Preclinical: 49 Clinical: 1 Phase-I: 25 Phase-I/II: 2 Phase-II: 26 Phase-II/III: 2 Phase-III: 5 Preregistration: 2 Marketed: 10 Unknown: 1
January 2014
265 pages
US Cancer Vaccine Pipeline Analysis
US$ 1,500.00
... for entry. Constituting almost 50% of the global pie, the US cancer vaccine market was estimated to be worth USD 14 Billion in 2012. With close ... cancer every year, this market is expected to o reach USD 20 billion by 2020. “US Cancer Vaccine Pipeline Analysis” by PNS Pharma gives comprehensive insight on the ...
January 2014
300 pages
Global Monoclonal Antibodies Pipeline Analysis
US$ 1,800.00
... when purchasing Hard Copy License depending on the location. The market for monoclonal antibodies (mAB) has become the fastest growing segment ... for each orphan designated drug profile in development phase are covered in “Global Monoclonal Antibodies Pipeline Analysis” research report: Drug Profile Overview ...
January 2014
1360 pages
Europe Parkinson’s Disease Drug Pipeline Analysis
US$ 1,000.00
... for Clinical Trial Owner / Originator/ Licensee/Collaborator Administrative Route Drug Class ATC Codes Europe Parkinson’s Disease Drug Pipeline by Clinical Phase: Research: 12 Clinical: 26 Phase-I: 14 Phase-I/II: 2 Phase-II: 6 Phase-II/III: 1 Phase-III: 3 Preregistration: 1 Marketed: 18
January 2014
199 pages
US Skin Cancer Drug Pipeline Analysis
US$ 1,200.00
... Trial Owner / Originator/ Licensee/Collaborator Administrative Route Drug Class ATC Codes Number of Skin Cancer Drug in Pipeline by Clinical Phase: Research: 3 Preclinical: 29 Clinical: 5 Phase 0: 1 Phase-I: 29 Phase-I/II: 18 Phase-II: 41 Phase-III: 13 Registered: 4 Marketed: 18 Unknown: 1
January 2014
310 pages
Japan Cancer Drug Pipeline Analysis
US$ 1,500.00
... for the pharma companies in their every-day decision making. “Japan Cancer Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various ... to identify and analyze the available investment opportunity in the Japan cancer drug market based upon development process. Following parameters for ...
January 2014
557 pages
Europe Lung Cancer Drug Pipeline Analysis
US$ 1,200.00
... identify and analyze the available investment opportunity in the Europe lung cancer drug market based upon development process. Following parameters for ... drug profile in development phase are covered in “Europe Lung Cancer Drug Pipeline Analysis” research report: Drug Profile Overview Alternate Names for ...
January 2014
340 pages
Europe Orphan Drug Pipeline Analysis 2014
US$ 2,400.00
... in the Europe orphan designated drug market based upon development process. Following parameters for each drug profile in development phase are covered in “Europe Orphan Drug Pipeline Analysis 2014” research report: Drug Profile Overview Active Indication ...
January 2014
1430 pages
Global Vaccine Market Pipeline Analysis
US$ 1,500.00
... sub-divided into four groups namely, pediatrics, adolescents, adults and elderly. Though the vaccines segment forms a very small portion of the ... market is expected to surpass estimated USD 100 billion by 2025. “Global Vaccine Market Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various ...
January 2014
1150 pages
US Lung Cancer Drug Pipeline Analysis
US$ 1,800.00
... annual statistics published, an estimated 201,144 people in the United States were diagnosed with lung cancer. This figure included 107,164 men and ... drug market based upon development process. Following parameters for each drug profile in development phase are covered in “US Lung Cancer Drug Pipeline Analysis ...
November 2013
385 pages
US Colorectal Cancer Drug Pipeline Analysis
US$ 1,500.00
... that the US would witness a modest increase in the prevalence of the disease, mostly as a result of the country having already reached epidemic proportions ... market based upon development process. Following parameters for each drug profile in development phase are covered in “US Colorectal Cancer Drug Pipeline ...
November 2013
242 pages
US Parkinson's Disease Drug Pipeline Analysis
US$ 1,500.00
... in the near future. It has been estimated that at least 500,000 people in the United States currently have been diagnosed with this disease. ... drug market based upon development process. Following parameters for each drug profile in development phase are covered in “US Parkinson’s Disease Drug Pipeline Analysis ...
November 2013
241 pages
Global Cancer Monoclonal Antibodies Pipeline Analysis
US$ 1,500.00
... Pharma gives comprehensive insight on the various Monoclonal Antibodies being developed for the treatment of Cancer. Research report covers all the ... profile in development phase are covered in “Global Cancer Monoclonal Antibodies Pipeline Analysis” research report: Drug Profile Overview Alternate Names for ...
November 2013
660 pages
Global RNAi Drug Pipeline Analysis
US$ 1,500.00
... location. “Global RNAi Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drugs being developed based upon RNAi technology. ... Drug market based upon development process. Following parameters for each drug profile in development phase are covered in “Global RNAi Drug Pipeline ...
October 2013
250 pages
Global DNA Vaccine Pipeline Analysis
US$ 1,500.00
... West Nile Virus to be used in horses was approved in 2005. 'Global DNA Vaccine Pipeline Analysis' by PNS Pharma gives comprehensive insight on the various ... holders to identify and analyze the available investment opportunity in the DNA vaccine market based upon development process. Following parameters for ...
October 2013
130 pages
US Orphan Drug Pipeline Analysis
US$ 1,800.00
... from rare disease. In US, this pool of patients is gradually growing and orphan drugs are becoming an extremely attractive business proposition for the ... increasing, thus increasing the profit margins in the future. “US Orphan Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various ...
October 2013
880 pages
Global Oncolytic Virus Therapy Pipeline Analysis
US$ 1,500.00
... survival solutions with significant importance. Also, the side effects of this therapy would be tolerable by the patients, which could thus become the ... selective without the need for any genetic manipulation. “Global Oncolytic Virus Therapy Pipeline Analysis” by PNS Pharma gives comprehensive insight on the ...
October 2013
105 pages
Global Infertility Drug Pipeline Analysis
US$ 1,000.00
... drugs and treatment. The most lucrative markets for infertility drugs are the emerging nations such as India, Brazil, China and Mexico, ... pool of people being affected by lifestyle diseases, thus leading to infertility. “Global Infertility Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the ...
October 2013
60 pages
Orphan Drugs for Cancer Pipeline Analysis
US$ 1,800.00
... patient population which suffers from rare or orphan diseases. Among the category of new orphan drugs, Oncology account for the largest disease group ... drug profile in development phase are covered in “Orphan Drugs for Cancer Pipeline Analysis” research report: Drug Profile Overview Alternate Names for Drug ...
October 2013
855 pages
Global HIV Infection Drug Pipeline Analysis
US$ 1,500.00
... to identify and analyze the available investment opportunity in the HIV Infection drug market based upon development process. Following parameters for each drug profile in clinical development phase are covered in “Global HIV Infection Drug Pipeline Analysis” research report: Drug ...
October 2013
300 pages
